$1.16
7.41% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US72941H4002
Symbol
PSTV
Sector
Industry

Plus Therapeutics Inc Stock price

$1.16
-0.10 7.94% 1M
-0.30 20.55% 6M
-0.59 33.72% YTD
-0.68 36.96% 1Y
-15.79 93.16% 3Y
-36.19 96.89% 5Y
-55,517.59 100.00% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.08 7.41%
ISIN
US72941H4002
Symbol
PSTV
Sector
Industry

Key metrics

Market capitalization $6.84m
Enterprise Value $5.45m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.95
P/S ratio (TTM) P/S ratio 1.19
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 52.63%
Revenue (TTM) Revenue $5.73m
EBIT (operating result TTM) EBIT $-14.66m
Free Cash Flow (TTM) Free Cash Flow $-11.40m
Cash position $4.79m
EPS (TTM) EPS $-2.24
P/E forward negative
P/S forward 1.08
EV/Sales forward 0.86
Short interest 0.90%
Show more

Is Plus Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Plus Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

4 Analysts have issued a Plus Therapeutics Inc forecast:

4x Buy
100%

Analyst Opinions

4 Analysts have issued a Plus Therapeutics Inc forecast:

Buy
100%

Financial data from Plus Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
5.73 5.73
53% 53%
100%
- Direct Costs 0.80 0.80
6% 6%
14%
4.92 4.92
70% 70%
86%
- Selling and Administrative Expenses 7.59 7.59
6% 6%
132%
- Research and Development Expense 11 11
24% 24%
195%
-14 -14
2% 2%
-242%
- Depreciation and Amortization 0.80 0.80
6% 6%
14%
EBIT (Operating Income) EBIT -15 -15
3% 3%
-256%
Net Profit -13 -13
15% 15%
-225%

In millions USD.

Don't miss a Thing! We will send you all news about Plus Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Plus Therapeutics Inc Stock News

Neutral
GlobeNewsWire
12 days ago
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breas
Neutral
GlobeNewsWire
25 days ago
Company to present ReSPECT-LM Phase 1 trial data on Rhenium ( 186 Re) Obisbemeda with a focus on treating leptomeningeal metastases (LM) in breast cancer patients AUSTIN, Texas, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for c...
Neutral
GlobeNewsWire
26 days ago
AUSTIN, Texas, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics , Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on developing innovative radiotherapeutics, today announced the renewal of its Master Services Agreement (MSA) with Telix IsoTherapeutics Group Inc. (‘IsoTherapeutics', a Telix Group company). This MSA secures a reliable supply of cGMP Re-186, the radioisotop...
More Plus Therapeutics Inc News

Company Profile

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in the discovery, development, and delivery of complex and innovative treatments for patients battling cancer and rare diseases. Its products include Rhenium NanoLiposome (RNL) and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Austin, TX.

Head office United States
CEO Marc Hedrick
Employees 20
Founded 1996
Website www.plustherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today